BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32772084)

  • 1. Features of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery.
    Endo M; Porter K; Long C; Azaryan I; Phay JE; Ringel MD; Sipos JA; Nabhan F
    J Clin Endocrinol Metab; 2020 Nov; 105(11):e3971-80. PubMed ID: 32772084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of cancer and the benign call rate of afirma gene classifier in
    Endo M; Sipos JA; Ringel MD; Porter K; Nagaraja HN; Phay JE; Shirley LA; Long C; Wright CL; Roll K; Nabhan FA
    Cancer Med; 2021 Feb; 10(3):1084-1090. PubMed ID: 33449450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL; Faquin WC; Samir AE
    AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between the ultrasonography TIRADS classification system and surgical pathology among indeterminate thyroid nodules.
    Sahli ZT; Karipineni F; Hang JF; Canner JK; Mathur A; Prescott JD; Sheth S; Ali SZ; Zeiger MA
    Surgery; 2019 Jan; 165(1):69-74. PubMed ID: 30415866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up.
    Angell TE; Frates MC; Medici M; Liu X; Kwong N; Cibas ES; Kim MI; Marqusee E
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1477-83. PubMed ID: 26353010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIRADS Interobserver Variability Among Indeterminate Thyroid Nodules: A Single-Institution Study.
    Sahli ZT; Sharma AK; Canner JK; Karipineni F; Ali O; Kawamoto S; Hang JF; Mathur A; Ali SZ; Zeiger MA; Sheth S
    J Ultrasound Med; 2019 Jul; 38(7):1807-1813. PubMed ID: 30467876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
    Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.
    Duick DS; Klopper JP; Diggans JC; Friedman L; Kennedy GC; Lanman RB; McIver B
    Thyroid; 2012 Oct; 22(10):996-1001. PubMed ID: 22873825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 14. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
    McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter clinical experience with the Afirma gene expression classifier.
    Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
    J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
    Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.